Compare · MGTX vs RGNX
MGTX vs RGNX
Side-by-side comparison of MeiraGTx Holdings plc (MGTX) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGTX and RGNX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MGTX is the larger of the two at $1.07B, about 2.2x RGNX ($493.1M).
- Over the past year, MGTX is up 35.1% and RGNX is down 23.0% - MGTX leads by 58.1 points.
- MGTX has been more active in the news (5 items in the past 4 weeks vs 3 for RGNX).
- RGNX has more recent analyst coverage (23 ratings vs 4 for MGTX).
- Company
- MeiraGTx Holdings plc
- REGENXBIO Inc.
- Price
- $11.13-0.04%
- $7.43-0.60%
- Market cap
- $1.07B
- $493.1M
- 1M return
- -19.38%
- -23.19%
- 1Y return
- +35.09%
- -23.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2015
- News (4w)
- 5
- 3
- Recent ratings
- 4
- 23
MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest MGTX
- SEC Form 4 filed by Director Sebulsky Alan
- New insider Sebulsky Alan claimed ownership of 34,500 units of Ordinary Shares (SEC Form 3)
- Goldman initiated coverage on MeiraGTx with a new price target
- MeiraGTx Holdings plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
- Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
- PRESIDENT & CEO Forbes Alexandria sold $859,320 worth of Ordinary Shares (62,000 units at $13.86) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,325,695 units (SEC Form 4)
- SEC Form 144 filed by MeiraGTx Holdings plc
- SEC Form S-8 filed by MeiraGTx Holdings plc
- SEC Form 10-Q filed by MeiraGTx Holdings plc
Latest RGNX
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
- REGENXBIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- REGENXBIO to Participate in Upcoming Investor Conferences
- Chief Technology Officer Malzahn Craig covered exercise/tax liability with 234 shares, decreasing direct ownership by 0.28% to 81,960 units (SEC Form 4)
- Chief Financial Officer Chan Mitchell covered exercise/tax liability with 4,902 shares, decreasing direct ownership by 4% to 122,815 units (SEC Form 4)
- Director Ciongoli Gregory Austin was granted 15,432 shares and bought $949,381 worth of shares (102,603 units at $9.25) (SEC Form 4)
- SEC Form 3 filed by new insider Ciongoli Gregory Austin
- REGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
- REGENXBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits